Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistance

Reuters2026/08/11 18:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 with pembrolizumab in first-line metastatic Merkel cell carcinoma.
Trial targets about 118 patients in a 1:1 placebo injection-controlled design; top-line data expected in 2H 2027.
Program operates under an FDA Special Protocol Assessment; confirmatory trial not expected to be required.
VISTA inhibitor TBS-2025 planned to enter a Phase 1b/2 trial in relapsed or refractory mutNPM1 acute myeloid leukemia in 2H 2026; preliminary data targeted for 1H 2027.
$50 million credit facility and royalty transaction cited as non-equity funding, with runway projected through Q1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tuhura Biosciences releases corporate deck outlining strategy to tackle cancer immunotherapy resistance

You may also like

Crypto prices